Substantial effects of apolipoprotein E Ε4 on memory decline in very old age: Longitudinal findings from a population-based sample

Neurobiology of Aging

Volumn 34, Issue 12, 2013, Pages 2734-2739

  Praetorius, Marcus ^a   Thorvaldsson, Valgeir ^a   Hassing, Linda B ^a   Johansson, Boo ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

APOE; Cognition; Cognitive change; Cognitive performance; Oldest old

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E EPSILON 4; UNCLASSIFIED DRUG;

AGE DISTRIBUTION; AGED; ALLELE; AMNESIA; APOE GENE; APTITUDE TEST; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; COGNITION; CONTROLLED STUDY; DEMENTIA; DIABETES MELLITUS; DISEASE ASSOCIATION; EDUCATIONAL STATUS; EFFECT SIZE; FEMALE; GENE; GENETIC ASSOCIATION; HUMAN; HYPERTENSION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEMORY CONSOLIDATION; MENTAL PERFORMANCE; MOTOR PERFORMANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN FUNCTION; RECALL; RECOGNITION; SEMANTIC MEMORY; SEX DIFFERENCE; SHORT TERM MEMORY; VERY ELDERLY;

APOE; COGNITION; COGNITIVE CHANGE; COGNITIVE PERFORMANCE; OLDEST OLD;

AGED, 80 AND OVER; AGING; ALLELES; APOLIPOPROTEIN E4; COGNITION; DEMENTIA; FEMALE; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALE; MEMORY; MEMORY DISORDERS; MENTAL RECALL; NEUROPSYCHOLOGICAL TESTS; TWIN STUDIES AS TOPIC;

EID: 84884133413     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2013.06.002     Document Type: Article

References (30)

1. WHO Expert Committee in Diabetes Mellitus: second report. World Health Organ. Tech. Rep. Ser. 1980, 646:1-80.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders: DSM-III-R 1987, American Psychiatric Association, Washington, DC. third ed.
3. Bennett D.A., Schneider J.A., Wilson R.S., Bienias J.L., Berry-Kravis E., Arnold S.E. Amyloid mediates the association of apolipoprotein E e4 allele to cognitive function in older people. J.Neurol. Neurosurg. Psychiatry 2005, 76:1194-1199.
4. Bondi M.W., Jak A.J., Delano-Wood L., Jacobson M.W., Delis D.C., Salmon D.P. Neuropsychological contributions to the early identification of Alzheimer's Disease. Neuropsychol. Rev. 2008, 18:73-90.
5. Bondi M.W., Salmon D.P., Galasko D., Thomas R.G., Thal L.J. Neuropsychological function and apolipoprotein E genotype in the preclinical detection of Alzheimer's disease. Psychol. Aging 1999, 14:295-303.
6. Bretsky O., Guralnik J.M., Launer L., Albert M., Seeman T.E. The role of APOE-epsilon4, of APOE-epsilon4 in longitudinal cognitive decline: MacArthur studies of Successful Aging. Neurology 2003, 60:1077-1081.
7. Dureman L., Sälde H. Psykometriska och experimentalpsykologiska metoder för klinisk tillämpning 1959, Uppsala, Sweden.
8. Johansson B. The MIR-Memory-in-Reality Test 1988/1989, Psykologiförlaget AB, Stockholm.
9. Johansson B., Hofer S.M., Allaire J.C., Maldonado-Molina M.M., Piccinin A.M., Berg S., McClearn G.E. Change in cognitive capabilities in the oldest old: the effects of proximity to death in genetically related individuals over a 6-year period. Psychol. Aging 2004, 19:145-156.
10. Jonson C.O., Molander L. Manual of the CVB-Scales 1964, Psykologiförlaget AB, Stockholm.
11. Li S.C., Schmiedek F. Age is not necessarily aging: another step towards understanding the "clocks" that time aging. Gerontology 2002, 48:5-12. discussion, 22-19.
12. Mahley R.W., Weisgraber K.H., Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, factor and therapeutic target in neuropathology, including Alzheimer's Disease. Proc. Natl. Acad. Sci. U.S.A 2006, 103:5644-5651.
13. McClearn G.E., Johansson B., Berg S., Pedersen N.L., Ahern F., Petrill S.A., Plomin R. Substantial genetic influence on cognitive abilities in twins 80 or more years old. Science 1997, 276:1560-1563.
14. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
15. Nilsson S.E., Johansson B., Berg S., Karlsson D., McClearn G.E. Acomparison of diagnoses captured from medical records, self-reports, and drug registrations: a study in individuals 80 years and older. Aging Clin. Exp. Res. 2002, 14:178-184.
16. Packard C.J., Westendorp R.G., Stott D.J., Caslake M.J., Murray H.M., Shepherd J., Twomey C. Association between apolipoprotein E4 and cognitive decline in elderly adults. J.Am. Geriatr. Soc. 2007, 55:1777-1785.
17. Piccinin A.M., Muniz G., Matthews F.E., Johansson B. Terminal decline from within- and between-person perspectives, accounting for incident dementia. J.Gerontol. B Psychol. Sci. Soc. Sci. 2011, 66:391-401.
18. Reynolds C.A., Hong M.G., Eriksson U.K., Blennow K., Wiklund F., Johansson B., Prince J.A. Analysis of lipid pathway genes indicates association of sequence variation near SREBF1/TOM1L2/ATPAF2 with dementia risk. Hum. Mol. Genet. 2010, 19:2068-2078.
19. Roman G.C., Tatemichi T.K., Erkinjuntti T., Cummings J.L., Masdeu J.C., Garcia J.H., Amaducci L., Orgogozo J.M., Brun A., Hofman A., et al. Vascular dementia: diagnostic criteria for research studies. Reports of the NINDS-AIREN International Workshop. Neurology 1993, 43:250-260.
20. Schiepers O.J., Harris S.E., Gow A.J., Pattie A., Brett C.E., Starr J.M., Deary I.J. APOE E4 status predicts age-related cognitive decline in the nonth decade: longitudinal follow-up of the Lothian Birth Cohort 1921. Mol. Psychiatry 2011, 17:315-324.
21. Small B.J., Rosnick C.B., Fratiglioni L., Bäckman L. Apolipoprotein E and cognitive performance: a meta-analysis. Psychol. Aging 2004, 19:592-600.
22. Thorvaldsson V., Hofer S.M., Berg S., Skoog I., Sacuiu S., Johansson B. Onset of terminal decline in cognitive abilities in individuals without dementia. Neurology 2008, 71:882-887.
23. Thorvaldsson V., Nordlund A., Reinvang I., Blennow K., Zetterberg H., Wallin A., Johansson B. Memory in individuals with mild cognitive impairment in relation to APOE and CSF Abeta42. Int Psychogeriatr. 2010, 22:598-606.
24. Thurstone L.L., Thurstone T.G. Manual to SRA Primary Mental Abilities 1949, Chicago.
25. Wechsler D. Astandardized memory scale for clinical use. J.Psychol. 1945, 19:87-95.
26. Wechsler D. WAIS-R Manual 1981, Psychological Corporation, New York.
27. Wechsler D. Manual for the Wechsler Adult Inteligence-Scale Revised 1991, New York.
28. Wilson R.S., Segawa E., Hizel L.P., Boyle P.A., Bennett D.A. Terminal dedifferentiation of cognitive abilities. Neurology 2012, 78:1116-1122.
29. Wisdom N.M., Callahan J.L., Hawkins K.A. The effects of apolipoprotein E on non-impaired cognitive functioning: a meta-analysis. Neurobiol. Aging 2011, 32:63-74.
30. Yu, L., Boyle, P., Schneider, J.A., Segawa, E., Wilson, R.S., Leurgans, S., Bennett, D.A. APOE epsilon4, Alzheimer's Disease pathology, cerebrovascular disease, and cognitive change over the years prior to death. Psychol. Aging in press.